We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




X-ray Study Explains How Takinib Inhibits TNF-alpha

By LabMedica International staff writers
Posted on 29 Aug 2017
Takinib, a selective TAK1 inhibiting drug, has been shown to broaden the therapeutic efficacy of TNF-alpha (Tumor necrosis factor-alpha) inhibition for treating cancer and autoimmune diseases.

TAK1 (also known as MAP3K7 or mitogen-activated protein kinase kinase kinase 7) is a key mediator between survival and cell death in TNF-alpha-mediated signaling. More...
TNF-alpha is a cytokine that has a wide variety of functions. It can cause cytolysis of certain tumor cell lines and is a potent pyrogen, causing fever by direct action or by stimulation of interleukin-1 secretion. It can stimulate cell proliferation and induce cell differentiation under certain conditions.

Investigators at Duke University (Durham, NC, USA) recently described the compound Takinib, a potent and selective TAK1 inhibitor that induced apoptosis following TNF-alpha stimulation in cell models of rheumatoid arthritis and metastatic breast cancer.

The investigators used X-ray crystallography to demonstrate that Takinib was an inhibitor of autophosphorylated and non-phosphorylated TAK1 that bound within the ATP-binding pocket and inhibited TAK1 by slowing down the rate-limiting step of TAK1 activation.

Overall, the investigators saw Takinib as an attractive starting point for the development of inhibitors that sensitize cells to TNF-alpha-induced cell death, with general implications for cancer and autoimmune disease treatment.

"The delicate balance between survival and death is often disrupted in disease, and this molecule is able to target the process," said senior author Dr. Timothy Haystead, professor of pharmacology and cancer biology at Duke University. "This compound could potentially enhance the positive parts of TNF-alpha by only targeting tumor cells or inflammatory cells."

The study was published in the August 17, 2017, issue of the journal Cell Chemical Biology.

Related Links:
Duke University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Collection and Transport System
PurSafe Plus®
New
Blood Glucose Test Strip
AutoSense Test
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Colorectal cancer under the microscope (Photo courtesy of Adobe Stock)

Unique Microbial Fingerprint to Improve Diagnosis of Colorectal Cancer

Colorectal cancer is the fourth most common cancer in the UK and the second deadliest. New research has revealed that it carries a unique microbial fingerprint, which could help doctors better understand... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.